Literature DB >> 214676

Preparation and efficacy of an inactivated subunit vaccine (NFUIBHK) against type 2 Herpes simplex virus infection.

G R Skinner, D R Williams, A Buchan, J Whitney, M Harding, K Bodfish.   

Abstract

A vaccine against Herpes simplex virus infection was prepared by Nonidet NP 40 and formalin treatment of a type 1, infected-cell extract; virus particles were removed by ultracentrifugation over sucrose. These procedures were not detrimental to the antigenic quality of the vaccine preparation. The vaccine afforded significant protection to experimental type 2 genital herpes virus infection in mice, as adjudged by clinical observations, cytopathological change, and virus yields.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 214676     DOI： 10.1007/bf02121141

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN： 0300-8584            Impact factor:   3.402


  27 in total

1.  Production and some properties of neutralizing antigens of herpes simplex virus.

Authors:  L Kutinová; V Vonka; D Rezácová
Journal:  Acta Virol       Date:  1977-05       Impact factor: 1.162

2.  Interaction of herpes virus and HeLa cells: comparison of cell killing and infective center formation.

Authors:  J T VANTSIS; P WILDY
Journal:  Virology       Date:  1962-06       Impact factor: 3.616

3.  A sensitive and precise plaque assay for herpes virus.

Authors:  W C RUSSELL
Journal:  Nature       Date:  1962-09-08       Impact factor: 49.962

4.  Immunological control of cervical cancer: discussion.

Authors:  J L Melnick
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

5.  Polyoma transformation of hamster cell clones--an investigation of genetic factors affecting cell competence.

Authors:  I MACPHERSON; M STOKER
Journal:  Virology       Date:  1962-02       Impact factor: 3.616

6.  Transformation of rat embryo cells by temperature-sensitive mutants of herpes simplex virus.

Authors:  J C Macnab
Journal:  J Gen Virol       Date:  1974-07       Impact factor: 3.891

7.  Cytology and histopathology of cervical herpes simplex infection.

Authors:  Z M Naib; A J Nahmias; W E Josey
Journal:  Cancer       Date:  1966-07       Impact factor: 6.860

8.  Seroepidemiologic studies of herpesvirus type 2 and carcinoma of the cervix. IV. Dysplasia and carcinoma in situ.

Authors:  E Adam; R H Kaufman; J L Melnick; A H Levy; W E Rawls
Journal:  Am J Epidemiol       Date:  1973-08       Impact factor: 4.897

9.  Antibodies to type 1 and type 2 herpes virus in women with abnormal cervical cytology.

Authors:  G R Skinner; M E Thouless; J A Jordan
Journal:  J Obstet Gynaecol Br Commonw       Date:  1971-11

10.  Properties of hamster embryo fibroblasts transformed in vitro after exposure to ultraviolet-irradiated herpes simplex virus type 2.

Authors:  R Duff; F Rapp
Journal:  J Virol       Date:  1971-10       Impact factor: 5.103
View more
  15 in total

1.  Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.

Authors:  G R Skinner; C Fink; J Melling; C Wiblin; B Thornton; J Hallworth; W Gardner; P McLeish; C Hartley; A Buchan
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

2.  Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine.

Authors:  G R Skinner; C G Fink; M Cowan; A Buchan; A Fuller; C E Hartley; J Durham; C Wiblin; J Melling
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

3.  The influence of different modes of immunization on the experimental genital herpes simplex virus infection of mice.

Authors:  K E Schneweis; J Gruber; J Hilfenhaus; A Möslein; M Kayser; M H Wolff
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

4.  Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis.

Authors:  G R Skinner; C B Woodman; C E Hartley; A Buchan; A Fuller; J Durham; M Synnott; J C Clay; J Melling; C Wiblin; J Wilkins
Journal:  Br J Vener Dis       Date:  1982-12

5.  Immunogenicity and protective efficacy in a rhesus monkey model of vaccine Ac NFUi(S-) MRC against primary type 2 herpes simplex virus infection.

Authors:  G R Skinner; A Buchan; D Williams; J Marsden; C Hartley; G Wilbanks; M Turyk; E S Namkoong
Journal:  Br J Exp Pathol       Date:  1982-08

6.  Efficacy of vaccine Ac NFU1 (S-) MRC 5 given after an initial clinical episode in the prevention of herpes genitalis.

Authors:  C B Woodman; A Buchan; A Fuller; C Hartley; G R Skinner; D Stocker; D Sugrue; J C Clay; G Wilkins; C Wiblin
Journal:  Br J Vener Dis       Date:  1983-10

7.  Immunogenicity of purified glycoprotein gB of herpes simplex virus.

Authors:  Y Kino; T Eto; K Nishiyama; N Ohtomo; R Mori
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

8.  The preparation, efficacy and safety of 'antigenoid' vaccine NFU1 (S-L+) MRC toward prevention of herpes simplex virus infections in human subjects.

Authors:  G R Skinner; A Buchan; C E Hartley; S P Turner; D R Williams
Journal:  Med Microbiol Immunol       Date:  1980       Impact factor: 3.402

9.  The effect of lithium chloride on the replication of herpes simplex virus.

Authors:  G R Skinner; C Hartley; A Buchan; L Harper; P Gallimore
Journal:  Med Microbiol Immunol       Date:  1980       Impact factor: 3.402

10.  Animal studies on the efficacy of vaccination against recurrent herpes.

Authors:  M Scriba
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.